These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33809082)

  • 21. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
    Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
    J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics.
    Verheyen J; Maizus K; Feist E; Tolman Z; Knops E; Saech J; Spengler L; Waterboer T; Burmester GR; Pawlita M; Pfister H; Rubbert-Roth A
    Med Microbiol Immunol; 2015 Oct; 204(5):613-8. PubMed ID: 25678083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Schneider-Hohendorf T; Schulte-Mecklenbeck A; Ostkamp P; Janoschka C; Pawlitzki M; Luessi F; Zipp F; Meuth SG; Klotz L; Wiendl H; Gross CC; Schwab N
    Mult Scler; 2021 Sep; 27(10):1491-1496. PubMed ID: 33150829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH; Huang D
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral miRNAs in plasma and urine divulge JC polyomavirus infection.
    Lagatie O; Van Loy T; Tritsmans L; Stuyver LJ
    Virol J; 2014 Sep; 11():158. PubMed ID: 25178457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
    Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
    Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
    Bellizzi A; Anzivino E; Rodio DM; Cioccolo S; Scrivo R; Morreale M; Pontecorvo S; Ferrari F; Di Nardo G; Nencioni L; Carluccio S; Valesini G; Francia A; Cucchiara S; Palamara AT; Pietropaolo V
    Virol J; 2013 Sep; 10():298. PubMed ID: 24079660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells.
    O'Hara BA; Gee GV; Haley SA; Morris-Love J; Nyblade C; Nieves C; Hanson BA; Dang X; Turner TJ; Chavin JM; Lublin A; Koralnik IJ; Atwood WJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab.
    Mancuso R; Agostini S; Hernis A; Caputo D; Galimberti D; Scarpini E; Clerici M
    Front Neurol; 2022; 13():819911. PubMed ID: 35359635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA miR-J1-5p as a potential biomarker for JC virus infection in the gastrointestinal tract.
    Link A; Balaguer F; Nagasaka T; Boland CR; Goel A
    PLoS One; 2014; 9(6):e100036. PubMed ID: 24932487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.